Clinic
Lakeland Regional Medical Center, INC.
Lakeland Regional Medical Center, INC. was paid $61.98M by Medicaid between Jan 2018 and Dec 2024, across 374 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoLAKELAND REGIONAL MEDICAL CENTER, INC.
LAKELAND, FL 33805
LAKELAND, FL 33805
33aNPI1144228446assigned 07/11/2005
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$61.98M
24GClaims2,676,727
24DCodes billed374
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Florida
Rank by total paid#1 of 91
Median peer was paid$230K
This provider vs. median270×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GREEN, LANCE controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 171,792 | $2.43M | |
| 2019 | 530,697 | $8.45M | |
| 2020 | 408,306 | $8.70M | |
| 2021 | 541,956 | $13.98M | |
| 2022 | 519,292 | $13.86M | |
| 2023 | 327,171 | $8.97M | |
| 2024incomplete | 177,513 | $5.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 162,926 | 149,608 | $15.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 107,260 | 94,475 | $7.65M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 42,999 | 40,557 | $4.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 41,121 | 34,929 | $2.73M |
| J7030 | Infusion, normal saline solution , 1000 cc | 3.2% | 52,959 | 41,290 | $1.99M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 57,309 | 51,555 | $1.85M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 15,758 | 13,560 | $1.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 11,491 | 10,359 | $1.66M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 17,582 | 5,332 | $1.19M |
| 80051 | 1.9% | 107,501 | 85,931 | $1.16M | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 10,768 | 3,778 | $1.13M |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 1.8% | 2,726 | 652 | $1.10M |
362 more codes
| J3490 | Unclassified drugs | 1.4% | 11,683 | $867K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.2% | 24,094 | $719K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 61,132 | $705K |
| G0378 | Hospital observation service, per hour | 1.1% | 43,499 | $698K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 4,679 | $691K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 11,804 | $681K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 11,746 | $633K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,098 | $547K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,158 | $546K |
| 87070 | <1% | 16,866 | $519K | |
| 81003 | <1% | 17,351 | $446K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,715 | $445K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,923 | $438K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,898 | $371K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,053 | $369K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,568 | $367K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,866 | $338K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,931 | $311K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,335 | $305K |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,392 | $301K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,151 | $284K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 77,995 | $274K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,409 | $273K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,043 | $264K |
| 87486 | <1% | 13,512 | $242K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,284 | $226K |
| 84703 | <1% | 37,803 | $220K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28,719 | $215K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 4,061 | $199K |
| 97161 | <1% | 2,586 | $198K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,239 | $194K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,313 | $185K |
| 81001 | <1% | 57,157 | $182K | |
| 80053 | Comprehensive metabolic panel | <1% | 12,476 | $181K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15,492 | $172K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,906 | $154K |
| 12001 | <1% | 1,809 | $141K | |
| 74018 | <1% | 11,481 | $139K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,148 | $137K |
| 10060 | <1% | 1,738 | $136K | |
| 87420 | <1% | 11,688 | $134K | |
| 12011 | <1% | 1,667 | $134K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,126 | $133K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,318 | $128K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,171 | $126K |
| 94664 | <1% | 11,037 | $118K | |
| 73610 | <1% | 3,958 | $115K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,479 | $114K |
| 96367 | <1% | 4,334 | $110K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,761 | $109K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,699 | $106K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 757 | $99K |
| 97162 | <1% | 1,548 | $97K | |
| 84702 | <1% | 8,070 | $91K | |
| 73562 | <1% | 4,501 | $90K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,323 | $87K |
| 73630 | <1% | 4,301 | $85K | |
| 44970 | <1% | 86 | $85K | |
| 73130 | <1% | 3,208 | $85K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,300 | $85K |
| C1729 | Catheter, drainage | <1% | 537 | $83K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13,927 | $82K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,871 | $78K |
| 70491 | <1% | 544 | $77K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,753 | $77K |
| 92523 | <1% | 673 | $74K | |
| 73140 | <1% | 1,506 | $74K | |
| 96415 | <1% | 585 | $73K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 123,199 | $72K |
| 84112 | <1% | 1,316 | $71K | |
| 97165 | <1% | 588 | $65K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,867 | $65K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,685 | $65K |
| 71045 | Radiologic examination, chest; single view | <1% | 40,796 | $64K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,625 | $62K |
| 73110 | <1% | 2,374 | $62K | |
| 87077 | <1% | 6,924 | $60K | |
| A9270 | Non-covered item or service | <1% | 22,220 | $57K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,857 | $56K |
| 94644 | <1% | 5,679 | $54K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,158 | $54K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 300 | $53K |
| 87015 | <1% | 1,591 | $53K | |
| 73080 | <1% | 1,725 | $51K | |
| 92526 | <1% | 911 | $50K | |
| 76818 | <1% | 1,767 | $49K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,655 | $49K |
| 93017 | <1% | 1,601 | $47K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 789 | $45K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,723 | $45K |
| 12002 | <1% | 833 | $44K | |
| 76801 | <1% | 5,309 | $43K | |
| 70486 | <1% | 1,008 | $41K | |
| 87210 | <1% | 6,630 | $38K | |
| 73030 | <1% | 2,963 | $38K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,476 | $37K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 306 | $36K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 597 | $36K |
| 85610 | <1% | 20,915 | $35K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,276 | $35K |
| 93970 | <1% | 2,668 | $34K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,617 | $34K |
| 73590 | <1% | 2,190 | $34K | |
| 97166 | <1% | 340 | $34K | |
| 93971 | <1% | 1,655 | $32K | |
| C1769 | Guide wire | <1% | 1,558 | $32K |
| 73090 | <1% | 1,822 | $31K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,021 | $30K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 358 | $30K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,711 | $30K |
| 70250 | <1% | 488 | $29K | |
| 80076 | <1% | 45,237 | $27K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,528 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,191 | $26K |
| 87430 | <1% | 16,132 | $25K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 161 | $25K |
| 77336 | <1% | 41 | $25K | |
| 76770 | <1% | 1,415 | $25K | |
| 84484 | <1% | 41,335 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 354 | $24K |
| 82565 | <1% | 110,435 | $23K | |
| 87507 | <1% | 917 | $22K | |
| 72050 | <1% | 1,107 | $21K | |
| 80061 | Lipid panel | <1% | 4,762 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 40,562 | $20K |
| 86870 | <1% | 4,647 | $20K | |
| 72110 | <1% | 2,590 | $19K | |
| 47562 | <1% | 12 | $19K | |
| 82947 | <1% | 108,948 | $18K | |
| 70360 | <1% | 559 | $18K | |
| 93458 | <1% | 46 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,120 | $17K |
| 73502 | <1% | 1,766 | $17K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 958 | $16K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 379 | $15K |
| 52000 | <1% | 27 | $15K | |
| 84520 | <1% | 92,225 | $14K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 524 | $14K |
| S0028 | Injection, famotidine, 20 mg | <1% | 114 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,132 | $13K |
| 36430 | <1% | 145 | $12K | |
| 97116 | <1% | 982 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 28 | $12K |
| 85730 | <1% | 11,885 | $12K | |
| 73552 | <1% | 966 | $12K | |
| 73060 | <1% | 760 | $12K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 56 | $12K |
| 86850 | <1% | 3,415 | $12K | |
| 92610 | <1% | 265 | $12K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,046 | $11K |
| 29125 | <1% | 1,852 | $11K | |
| 24640 | <1% | 59 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,271 | $11K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,959 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,552 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 47 | $10K |
| 82805 | <1% | 2,891 | $10K | |
| 82247 | <1% | 1,555 | $10K | |
| 73660 | <1% | 237 | $10K | |
| 76870 | <1% | 622 | $10K | |
| 86140 | <1% | 5,925 | $10K | |
| 83735 | <1% | 13,851 | $10K | |
| 72072 | <1% | 841 | $10K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 22 | $9K |
| 87905 | <1% | 6,582 | $9K | |
| 83880 | <1% | 9,271 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,767 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,792 | $8K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,151 | $8K |
| 82607 | <1% | 1,653 | $7K | |
| 72131 | <1% | 200 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,449 | $7K |
| 70210 | <1% | 696 | $7K | |
| 29515 | <1% | 1,457 | $7K | |
| 87205 | <1% | 17,619 | $7K | |
| 86803 | <1% | 1,196 | $7K | |
| 87040 | <1% | 10,839 | $6K | |
| 74022 | <1% | 1,992 | $6K | |
| 96376 | <1% | 8,985 | $6K | |
| 85379 | <1% | 8,543 | $6K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 320 | $6K |
| 74174 | <1% | 50 | $6K | |
| 71250 | <1% | 184 | $6K | |
| 99201 | <1% | 580 | $6K | |
| 00840 | <1% | 470 | $6K | |
| 88342 | <1% | 1,512 | $6K | |
| 85027 | <1% | 3,326 | $5K | |
| 71101 | <1% | 381 | $5K | |
| 95816 | <1% | 42 | $5K | |
| 88307 | <1% | 215 | $5K | |
| 87075 | <1% | 729 | $5K | |
| 85014 | <1% | 21,665 | $5K | |
| 97010 | <1% | 58 | $5K | |
| 84439 | <1% | 3,394 | $5K | |
| 84132 | <1% | 2,892 | $5K | |
| 72100 | <1% | 423 | $4K | |
| 72170 | <1% | 767 | $4K | |
| 74019 | <1% | 421 | $4K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 408 | $4K |
| 70496 | <1% | 34 | $4K | |
| 83690 | <1% | 33,300 | $4K | |
| 76937 | <1% | 436 | $4K | |
| 84156 | <1% | 1,373 | $4K | |
| 76377 | <1% | 473 | $4K | |
| 97597 | <1% | 30 | $4K | |
| 77300 | <1% | 15 | $4K | |
| 86308 | <1% | 1,101 | $4K | |
| 86900 | <1% | 7,923 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 354 | $3K |
| 82310 | <1% | 3,556 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,506 | $3K |
| 49083 | <1% | 42 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,006 | $3K |
| 82550 | <1% | 4,325 | $3K | |
| 82570 | <1% | 1,346 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 58 | $3K |
| 82553 | <1% | 4,069 | $3K | |
| 82657 | <1% | 30 | $3K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 14 | $3K |
| 87186 | <1% | 5,341 | $3K | |
| 29105 | <1% | 362 | $3K | |
| 29505 | <1% | 627 | $3K | |
| 82728 | <1% | 1,196 | $3K | |
| 88300 | <1% | 49 | $3K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 298 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 31,628 | $3K |
| 83605 | <1% | 8,298 | $3K | |
| 90714 | <1% | 2,306 | $2K | |
| 86901 | <1% | 7,857 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,085 | $2K |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 765 | $2K |
| 88304 | <1% | 941 | $2K | |
| 84100 | <1% | 2,974 | $2K | |
| 97602 | <1% | 81 | $2K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 598 | $2K |
| 97113 | <1% | 36 | $2K | |
| 85651 | <1% | 4,755 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,684 | $2K |
| 69200 | <1% | 12 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,999 | $2K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 42 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13,643 | $1K |
| 84145 | <1% | 2,159 | $1K | |
| 87081 | <1% | 390 | $1K | |
| 84481 | <1% | 2,348 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 3,381 | $1K |
| 29130 | <1% | 265 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 583 | $1K |
| 87808 | <1% | 6,757 | $908.78 | |
| 87340 | <1% | 292 | $845.22 | |
| 82140 | <1% | 749 | $809.78 | |
| 96402 | <1% | 14 | $809.54 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,909 | $770.81 |
| 87147 | <1% | 1,493 | $724.45 | |
| 72040 | <1% | 107 | $711.78 | |
| 73100 | <1% | 14 | $710.97 | |
| 70160 | <1% | 12 | $655.00 | |
| 80164 | <1% | 294 | $647.08 | |
| 93880 | <1% | 82 | $605.60 | |
| 70498 | <1% | 16 | $601.44 | |
| 73560 | <1% | 93 | $577.80 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 32 | $574.78 |
| 69209 | <1% | 55 | $574.10 | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 17 | $540.38 |
| 80143 | <1% | 1,201 | $532.57 | |
| 96417 | <1% | 565 | $511.18 | |
| 80069 | <1% | 98 | $510.98 | |
| 87581 | <1% | 13,502 | $407.06 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 467 | $392.75 |
| 86769 | <1% | 184 | $391.93 | |
| 0002A | <1% | 92 | $360.00 | |
| 83540 | <1% | 548 | $349.35 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,426 | $322.15 |
| 86141 | <1% | 3,115 | $320.45 | |
| 83615 | <1% | 750 | $309.45 | |
| 97164 | <1% | 13 | $309.12 | |
| 80329 | <1% | 52 | $261.02 | |
| 82010 | <1% | 1,135 | $258.50 | |
| 84550 | <1% | 266 | $250.04 | |
| 86706 | <1% | 50 | $230.94 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 89 | $221.97 |
| 82077 | <1% | 3,026 | $212.85 | |
| 85045 | <1% | 1,069 | $191.12 | |
| 73620 | <1% | 68 | $162.86 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 39 | $160.06 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 102 | $147.35 |
| 82150 | <1% | 1,205 | $144.03 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 498 | $138.80 |
| 90686 | <1% | 475 | $137.27 | |
| 0012A | <1% | 196 | $136.78 | |
| 82248 | <1% | 1,109 | $133.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,464 | $122.69 |
| 86592 | <1% | 83 | $117.62 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,304 | $117.33 |
| 10061 | <1% | 13 | $107.94 | |
| 0011A | <1% | 209 | $101.64 | |
| 86923 | <1% | 199 | $100.92 | |
| 84466 | <1% | 250 | $97.14 | |
| 87045 | <1% | 1,292 | $95.61 | |
| 86780 | <1% | 243 | $93.13 | |
| 82746 | <1% | 187 | $91.53 | |
| 73120 | <1% | 14 | $88.98 | |
| 99406 | <1% | 64 | $86.40 | |
| 0001A | <1% | 88 | $84.70 | |
| 82330 | <1% | 993 | $84.39 | |
| 87427 | <1% | 2,194 | $75.06 | |
| 76000 | <1% | 14 | $73.02 | |
| 76882 | <1% | 13 | $71.05 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 350 | $69.65 |
| 87046 | <1% | 1,205 | $68.10 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 19 | $59.82 |
| 87899 | <1% | 61 | $59.65 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,147 | $57.57 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 231 | $56.77 |
| 85055 | <1% | 258 | $53.93 | |
| 80185 | <1% | 43 | $50.82 | |
| 89051 | <1% | 194 | $39.57 | |
| 73000 | <1% | 12 | $36.77 | |
| 94760 | <1% | 1,062 | $35.01 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 28 | $33.65 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | <1% | 83 | $23.58 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 520 | $20.95 |
| 80179 | <1% | 1,148 | $14.40 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 12 | $10.21 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 351 | $10.16 |
| 85018 | <1% | 153 | $10.11 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,135 | $6.08 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,377 | $4.11 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 649 | $1.53 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 487 | $1.10 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 313 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 1,146 | $0.00 |
| 87154 | 0% | 12 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 47 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 54 | $0.00 |
| 82435 | 0% | 54 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 31 | $0.00 |
| 87206 | 0% | 15 | $0.00 | |
| S0074 | Injection, cefotetan disodium, 500 mg | 0% | 21 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 26 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 72 | $0.00 |
| 00790 | 0% | 44 | $0.00 | |
| 82945 | 0% | 27 | $0.00 | |
| 84157 | 0% | 27 | $0.00 | |
| 96368 | 0% | 47 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
| 80320 | 0% | 33 | $0.00 | |
| 51702 | 0% | 18 | $0.00 | |
| 87150 | 0% | 228 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 137 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 28 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 71 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 88 | $0.00 |
| 84295 | 0% | 56 | $0.00 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 40 | $0.00 |
| 76802 | 0% | 17 | $0.00 | |
| 51701 | 0% | 19 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 14 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 36 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 16 | $0.00 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 0% | 14 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREEN, LANCE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $12.09M |
| Lakeland Regional Health Systems, INC. | Winter Haven, FL | $80K |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $55K |
| Lakeland Regional Health System, INC. | Lakeland, FL | $29K |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $20K |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $13K |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $948.03 |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $888.47 |
| Lakeland Regional Health Systems, INC. | Auburndale, FL | $760.73 |
| Lakeland Regional Health Systems, INC. | Lakeland, FL | $0.00 |
| Lakeland Regional Health Systems, INC | Plant City, FL | $0.00 |
| Lakeland Regional Health Systems, INC | Lakeland, FL | $0.00 |
| Lakeland Regional Health System, INC | Lakeland, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.